Pfizer's COVID-19 vaccine for children aged six months to five years old has been provisionally approved by the Therapeutic Goods Administration.

The vaccine will require approval from immunisation body ATAGI before it can be rolled out to the public.

"Today's provisional approval is an important reminder for parents to speak to their healthcare professional about COVID-19 vaccination," Pfizer Australia and New Zealand medical director Dr Krishan Thiru said.

READ MORE: 'Extraordinary' scenes as massive storm lands in Florida

If opened to the public, a Pfizer vaccination course for under-fives will consist of three doses.

Children with COVID-19 are less likely to grow seriously ill than adults, but are still at risk of compications.

Moderna received approval in August for its vaccine for children aged six months to six years, but only for high-risk cases.

READ MORE: Russia drafting retirees into army, telling conscripts to buy their own supplies

About 70,000 children nationwide are deemed to be at high risk of developing serious illness if they contract COVID-19.

They are severely immunocompromised, have a disability, and those who have complex or multiple health conditions.

ATAGI has not yet recommended a COVID-19 vaccine be rolled out for all children under five.